{"commentary":{"count":115,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":65,"youtube":29,"podcast":21},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02446444\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ENZARAD","nct_id":"NCT02446444","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=enzarad-nct02446444. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"ENZARAD","arms":[{"description":"Enzalutamide 160 mg daily, by mouth, for 24 months from randomisation. All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)","label":"Enzalutamide","type":"EXPERIMENTAL"},{"description":"Conventional Non-steroidal Anti-androgen (NSAA), by mouth, for 6 months from randomisation.\n\nAll participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)","label":"Conventional Non-steroidal Anti-androgen (NSAA)","type":"ACTIVE_COMPARATOR"}],"collaborators":["Australian and New Zealand Urogenital and Prostate Cancer Trials Group","National Health and Medical Research Council, Australia","Cancer Trials Ireland","Trans Tasman Radiation Oncology Group","European Organisation for Research and Treatment of Cancer - EORTC"],"completion_date":{"date":"2026-06","type":"ESTIMATED"},"conditions":["Prostatic Neoplasms"],"enrollment":{"count":802,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Enzalutamide","type":"DRUG"},{"name":"Conventional NSAA","type":"DRUG"},{"name":"LHRHA","type":"DRUG"},{"name":"External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)","type":"RADIATION"}],"last_update":"2026-05-06","lead_sponsor":"University of Sydney","official_title":"Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer: ENZARAD","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Metastasis-free survival","timeFrame":"5 years"}],"references":[],"start_date":{"date":"2014-03"},"study_type":"INTERVENTIONAL","title":"Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT02446444"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/enzarad-nct02446444"}